Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As obesity prevalence rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have set new standards in weight-loss drugs. Led by Novo Nordisk’s Wegovy (semaglutide), these therapies are driving rapid growth of the obesity therapy market and are on a path to transform the therapeutic landscape. Wegovy and Eli Lilly’s Zepbound (tirzepatide) are the most advanced antiobesity therapies, offering significantly greater weight-loss efficacy than that of Novo Nordisk’s Saxenda. Older treatments such as phentermine, Contrave, Qsymia, and Xenical are also losing favor despite their lower costs. This report provides in-depth analysis and insight into how prescription weight-loss drugs are used to treat obesity and how medical practice is evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed obese / overweight patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed obese patients?
- How have the GLP-1 RA products been integrated into the treatment algorithm, and what is its source of business?
- What percentage of obese / overweight patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of obese / overweight patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key drugs: Zepbound, Wegovy, Saxenda, Qsymia, Contrave, Xenical
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
